|
|
1. Buckley LM, Marquez M, Hudson JO,
et al. Variations in physicians' judgments about corticosteroid
induced osteoporosis by physician specialty. J Rheumatol.
1998;25:2195-2202. |
2. Adler RA, Hochberg MC. Suggested
guidelines for evaluation and treatment of glucocorticoid-induced
osteoporosis for the Department of Veterans Affairs. Arch
Intern Med. 2003;163:2619-2624. |
3. van Staa TP, Leufkens HG, Cooper
C. Use of inhaled corticosteroids and risk of fractures. J
Bone Miner Res. 2001;16:581-588. |
4. Lukert BP, Raisz LG. Glucocorticoid-induced
osteoporosis: pathogenesis and management. Ann Intern
Med. 1990;112:352-364. |
5. Adinoff AD, Hollister JR. Steroid-induced
fractures and bone loss in patients with asthma. N Engl
J Med. 1983;309:265-268. |
6. van Staa TP, Leufkens HG, Abenhaim
L, Zhang B, Cooper C.Use of oral corticosteroids and risk
of fractures. J Bone Miner Res. 2000; 15: 993-1000. |
7. Canalis E. Mechanisms of glucocorticoid
action in bone; implications to glucocorticoid induced osteoporosis. J
Clin Endocrinol Metab. 1996;81:3441-3447. |
8. Lukert BP, Raisz LG. Glucocorticoid-induced
osteoporosis. Rheum Dis Clin North Am. 1994;20:629-650. |
9. Canalis E, Bilezikian JP, Angeli
A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004;
34:593-598 |
10. Lipworth BJ. Systemic adverse effects
of inhaled corticosteroid therapy: A systematic review and
meta-analysis. Arch Intern Med. 1999;159:941-955. |
11. Sorkness CA. Establishing a therapeutic
index for the inhaled corticosteroids: part II. Comparisons
of systemic activity and safety among different inhaled
corticosteroids. J Allergy Clin Immunol. 1998;102:S52-64. |
12. Li JT, Ford LB, Chervinsky P, et
al. Fluticasone propionate powder and lack of clinically
significant effects on hypothalamic-pituitary-adrenal axis
and bone mineral density over 2 years in adults with mild
asthma. J Allergy Clin Immunol. 1999;103:1062-1068. |
13. Allen HD, Thong IG,
Clifton-Bligh P, Holmes S, Nery L, Wilson KB. Effects of
high-dose inhaled corticosteroids on bone metabolism in
prepubertal children with asthma. Pediatr Pulmonol.
2000;29:188-193. |
14. Harris M, Hauser S, Nguyen TV,
et al. Bone mineral density in prepubertal asthmatics receiving
corticosteroid treatment. J Paediatr Child Health. 2001;37:67-71. |
15. Recommendations for the prevention
and treatment of glucocorticoid-induced osteoporosis: 2001
update. American College of Rheumatology Ad Hoc Committee
on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44:1496-1503. |
16. Bone health and osteoporosis: A
report of the Surgeon General.Rockville, MD: U.S. Department
of Health and Human Services; 2004 http://www.surgeongeneral.gov/library/bonehealth/ |
17. Physician’s Guide to Prevention
and Treatment of Osteoporosis. 2nd ed. Washington, DC: National
Osteoporosis Foundation; 2003 http://www.nof.org. |
18. Recommendations for the prevention
and treatment of glucocorticoid-induced osteoporosis. American
College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis
Rheum. 1996;39:1791-1801. |
19. Gluck OS, Murphy WA, Hahn TJ, Hahn
B. Bone loss in adults receiving alternate day glucocorticoid
therapy. Arth Rheum. 1981;24:892-898. |
20. Saag KG. Low-dose corticosteroid
therapy in rheumatoid arthritis: balancing the evidence. Am
J Med. 1997;103:31S-39S. |
21. Saag KG, Koehnke R,
Caldwell JR, et al. Low dose long-term corticosteroid therapy
in rheumatoid arthritis: an analysis of serious adverse
events. Am J Med. 1994;96:115-123. |
22. Adachi JD, Saag KG, Delmas PD,
et al. Two-year effects of alendronate on bone mineral density
and vertebral fracture in patients receiving glucocorticoids:
a randomized, double-blind, placebo-controlled extension
trial. Arthritis Rheum. 2001;44:202-211. |
23. Wallach S, Cohen S, Reid DM, et
al. Effects of risedronate treatment on bone density and
vertebral fracture in patients on corticosteroid therapy. Calcif
Tissue Int. 2000;67:277-285. |
24. Reid DM, Hughes RA, Laan RF, et
al. Efficacy and safety of daily risedronate in the treatment
of corticosteroid-induced osteoporosis in men and women:
a randomized trial. European Corticosteroid-Induced Osteoporosis
Treatment Study. J Bone Miner Res. 2000;15:1006-1013. |
25. Cohen S, Levy RM, Keller M, et
al. Risedronate therapy prevents corticosteroid-induced
bone loss: a twelve-month, multicenter, randomized, double-blind,
placebo-controlled, parallel-group study. Arthritis
Rheum. 1999;42:2309-2318. |
26. Lane NE, Sanchez S, Modin GW, Genant
HK, Pierini E, Arnaud CD. Bone mass continues to increase
at the hip after parathyroid hormone treatment is discontinued
in glucocorticoid-induced osteoporosis: results of a randomized
controlled clinical trial. J Bone Miner Res. 2000;15:944-951. |
27. Adachi JD, Bensen WG, Bell MJ,
et al. Salmon calcitonin nasal spray in the prevention of
corticosteroid-induced osteoporosis. Br J Rheumatol.
1997;36:255-259. |
28. Healey JH, Paget SA, Williams-Russo
P, et al. A randomized controlled trial of salmon calcitonin
to prevent bone loss in corticosteroid-treated temporal
arteritis and polymyalgia rheumatica. Calcif Tissue
Int. 1996;58:73-80. |
|
|
